Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue—
Net Income-$13.28M-$13.28MN/M vs Q3 2022 EPS Diluted-$0.49-$0.49N/M vs Q3 2022 Operating Income-$14,351,000N/M Operating Cash Flowderived-$11,125,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$11,155,000N/M ended Sep 30, 2023 · filed Nov 2, 2023 · 33 d after period end